Patents by Inventor Shengfang Jin

Shengfang Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20240071588
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: January 13, 2023
    Publication date: February 29, 2024
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20200281501
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: February 14, 2020
    Publication date: September 10, 2020
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • Methods for diagnosing IDH-mutant cell proliferation disorders
    Patent number: 10711314
    Abstract: Methods of diagnosing subjects having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with mutant IDH enzymes with 2HG neoactivity.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 14, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • Methods and compositions for cell-proliferation-related disorders
    Patent number: 10610125
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 7, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS
    Publication number: 20190276894
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: April 26, 2018
    Publication date: September 12, 2019
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • Method for treating cell proliferation related disorders
    Patent number: 9982309
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 29, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20170325708
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 16, 2017
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun G. Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20170044620
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: August 16, 2016
    Publication date: February 16, 2017
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • Methods and compositions for cell-proliferation-related disorders
    Patent number: 9434979
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 6, 2016
    Inventors: Shin-San Michael Su, Lenny Dang, Stefan Gross, Shengfang Jin, Valeria Fantin
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20150240286
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: October 2, 2014
    Publication date: August 27, 2015
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Leonard Luan C Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1
    Patent number: 8883438
    Abstract: Methods and compositions for treating and evaluating subjects having a neoactive mutation at residue 97 of IDH1 or 137 of IDH2.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 11, 2014
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lewis C. Cantley, Leonard Luan C Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20140187435
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: July 11, 2013
    Publication date: July 3, 2014
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Leonard Luan C. Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco Gerald Salituro, Jeffrey Owen Saunders, Shin-San Michael Su, Katharine Yen
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20130316385
    Abstract: Methods and compositions for treating and evaluating subjects having a neoactive mutation at residue 97 of IDH1 or 137 of IDH2.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 28, 2013
    Inventors: Lewis C. Cantley, Leonard Luan C Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20130288284
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: September 14, 2012
    Publication date: October 31, 2013
    Inventors: Leonard Luan C Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20130183281
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: April 20, 2012
    Publication date: July 18, 2013
    Inventors: Shin-San Michael Su, Lenny Dang, Stefan Gross, Shengfang Jin, Valeria Fantin
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20120121515
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: March 12, 2010
    Publication date: May 17, 2012
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shinsan Su, Katharine Yen
  • METHODS OF TREATING CANCER HAVING AN ABERRANT EGFR OR KRAS GENOTYPE
    Publication number: 20120041070
    Abstract: The invention relates to the treating cancer having an aberrant EGFR or KRAS genotype, with an AMPK activator, as well as related methods, compounds and compositions.
    Type: Application
    Filed: September 30, 2011
    Publication date: February 16, 2012
    Inventors: Shengfang Jin, Shinsan Su, Matthew Van Der Heiden
  • METHODS FOR BREAST CANCER SCREENING AND TREATMENT
    Publication number: 20100029734
    Abstract: A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy only if the cancer is determined to comprise an ER+ tumor. A method for treating breast cancer in a patient further comprises (c) administering to the patient, if so selected, an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A method for treating a breast tumor in a patient having SERM-resistant ER+ breast cancer comprises administering to the patient an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor.
    Type: Application
    Filed: May 6, 2009
    Publication date: February 4, 2010
    Applicant: Ore Pharmaceuticals Inc.
    Inventors: David White, Shengfang Jin, Robert Mark Coopersmith, Denzyl Fernandes, Xuena Lin
  • METHOD FOR TREATING ER+ BREAST CANCER
    Publication number: 20090012052
    Abstract: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.
    Type: Application
    Filed: April 9, 2008
    Publication date: January 8, 2009
    Applicant: Ore Pharmaceuticals Inc.
    Inventors: Robert Mark Coopersmith, David William White, Shengfang Jin, Denzyl Fernandes, Xuena Lin
  • BREAST CANCER SCREENING AND TREATMENT METHODS
    Publication number: 20080132474
    Abstract: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.
    Type: Application
    Filed: November 6, 2007
    Publication date: June 5, 2008
    Applicant: Gene Logic Inc.
    Inventors: Robert Mark Coopersmith, David William White, Shengfang Jin, Denzyl Fernandes, Xuena Lin